Non-invasive Fibrosis Testing in Patients with Chronic Hepatitis B

被引：0
作者：
Clément Lejealle
Laurent Castera
机构：
[1] Service d’Hépatologie, Hôpital Beaujon, Clichy, Assistance Publique - Hôpitaux de Paris, INSERM UMR 1149 Centre de Recherche pour l’inflammation, Universite Paris Diderot, 100 boulevard du General Leclerc, Clichy
来源：
Current Hepatology Reports | 2018年 / 17卷 / 4期
关键词：
ARFI; HBV; Magnetic resonance elastography; Non-invasive; Serum biomarkers; Shear wave elastography; Transient elastography; Treatment;
D O I：
10.1007/s11901-018-0439-1
中图分类号：
学科分类号：
摘要：
Purpose of Review: Summarizing the available evidence and advantages and disadvantages of the use of non-invasive tests for the management of patients with chronic hepatitis B virus (HBV) infection, including before and during antiviral therapy. Recent Findings: Staging of liver fibrosis and early detection of compensated cirrhosis are critical in the treatment decisions and surveillance of HBV patients. Non-invasive assessment of liver fibrosis has been one of the major advances in hepatology over the past decade, relying either on the dosage of serum biomarkers or on the measurement of liver stiffness, using either ultrasound- or magnetic resonance-based elastography techniques. The most widely used and validated tests in HBV patients are APRI, FIB-4 (non-patented), and FibroTest-Fibrosure® (patented) for serum biomarkers and transient elastography. Liver stiffness also has prognostic value in the context of cirrhosis. Summary: Non-invasive tests are now recommended by national and international guidelines as first-line tools for fibrosis assessment. © Springer Science+Business Media, LLC, part of Springer Nature 2018.
引用
收藏
页码：492 / 501
页数：9
相关论文
共 115 条
[1]  
Schweitzer A., Horn J., Mikolajczyk R.T., Krause G., Ott J.J., Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013, Lancet, 386, pp. 1546-1555, (2015)
[2]  
Bravo A.A., Sheth S.G., Chopra S., Liver biopsy, N Engl J Med, 344, 7, pp. 495-500, (2001)
[3]  
Clinical practice guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 2, pp. 370-398, (2017)
[4]  
Castera L., Pinzani M., Non-invasive assessment of liver fibrosis: are we ready?, Lancet, 375, 9724, pp. 1419-1420, (2010)
[5]  
Bedossa P., Carrat F., Liver biopsy: the best, not the gold standard, J Hepatol, 50, 1, pp. 1-3, (2009)
[6]  
non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 63, 1, pp. 237-264, (2015)
[7]  
Dietrich C., Bamber J., Berzigotti A., Bota S., Cantisani V., Castera L., Et al., EFSUMB Guidelines and Recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version), Ultraschall Med, 38, 4, pp. e16-e47, (2017)
[8]  
Ferraioli G., Wong V.W., Castera L., Berzigotti A., Sporea I., Dietrich C.F., Et al., Liver ultrasound elastography: an update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations, Ultrasound Med Biol, (2018)
[9]  
Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T., Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study, Lancet, 357, 9262, pp. 1069-1075, (2001)
[10]  
Myers R.P., Tainturier M.H., Ratziu V., Piton A., Thibault V., Imbert-Bismut F., Messous D., Charlotte F., di Martino V., Benhamou Y., Poynard T., Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B, J Hepatol, 39, 2, pp. 222-230, (2003)
12345678910